Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

Authors

Jason N. Moore, PharmD, Thomas Jefferson UniversityFollow
Marc Gastonguay, Metrum Research Group, Tariffville, CT
Susan C. Adeniyi-Jones, MD, Thomas Jefferson UniversityFollow
David E. Moody, University of UtahFollow
Walter K. Kraft, MD, FACP, Thomas Jefferson UniversityFollow

Files

Description

Neonatal abstinence syndrome (NAS) is a condition affecting newborns exposed to an opioid in utero. Symptoms of NAS include excessive crying, poor feeding, and disordered autonomic control. Up to 2/3 of infants will require pharmacologic therapies to reach symptom control. Opioids including morphine and methadone are the current first-line treatments. Buprenorphine is being investigated as a treatment of NAS. The purpose of this analysis was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of BUP in infants with NAS.

Poster presented at American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2017 Annual Meeting, March 15-18, 2017 in Washington DC.

Publication Date

3-17-2017

Keywords

Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

Disciplines

Pharmacy and Pharmaceutical Sciences

Recommended Citation

Moore, PharmD, Jason N.; Gastonguay, Marc; Adeniyi-Jones, MD, Susan C.; Moody, David E.; and Kraft, MD, FACP, Walter K., "Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome" (2017). Department of Pharmacology and Experimental Therapeutics Posters. 4.
https://jdc.jefferson.edu/petposters/4